Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia

被引：46
|
作者：
Leoni, Veronica [1 ]
Biondi, Andrea
机构：
[1] Milano Bicocca Univ, Paediat Haematol Oncol Dept, San Gerardo Hosp, Fdn MBBM, Monza, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷 / 03期
关键词：
STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; ADULT PATIENTS; HYPER-CVAD; ALLOGENEIC TRANSPLANTATION; MARROW TRANSPLANTATION; COMPLETE REMISSION; REDUCED-INTENSITY; ELDERLY-PATIENTS; IMATINIB;
D O I：
10.3324/haematol.2015.124016
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：295 / 299
页数：6
相关论文
共 50 条
  • [1] 2-DEOXY-D-GLUCOSE INDUCES APOPTOSIS IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AND SYNERGIZES WITH BCR/ABL TYROSINE KINASE INHIBITORS
    Barredo, Julio C.
    Leclerc, Guy J.
    Du, Jianfeng
    PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1035 - 1035
  • [2] BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
    Schiffer, Charles A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 258 - 265
  • [3] The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment
    Thomas, Xavier
    Heiblig, Mael
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (11) : 1061 - 1070
  • [4] Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia
    O'Dwyer, ME
    Druker, BJ
    CURRENT OPINION IN ONCOLOGY, 2000, 12 (06) : 594 - 597
  • [5] Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML
    Benjamini, Ohad
    Kantarjian, Hagop M.
    O'Brien, Susan
    Thomas, Deborah
    Ravandi, Farhad
    Jain, Preetesh
    Pierce, Sherry
    Borthakur, Gautam
    Kadia, Tapan M.
    Jabbour, Elias
    Estrov, Zeev
    Luthra, Rajyalakshmi
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [6] BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors
    Byun, Ja Min
    Koh, Youngil
    Shin, Dong-Yeop
    Kim, Inho
    Yoon, Sung-Soo
    Lee, Jeong-Ok
    Bang, Soo-Mee
    Kim, Ki Hwan
    Jung, Sung-Hoon
    Lee, Won Sik
    Park, Yong
    Jang, Jun Ho
    Han, Jae Joon
    Yhim, Ho-Young
    Kim, Dae Sik
    Lee, Yoo Jin
    Lee, Hyewon
    Choi, Yun-Suk
    Lee, Seok
    HAEMATOLOGICA, 2017, 102 (05) : E187 - E190
  • [7] The Protein Tyrosine Phosphatase STS-1 Interacts with Bcr-Abl and Impairs the Response of Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) to Tyrosine Kinase Inhibitors
    Liebermann, Marcus
    Hoeller, Daniela
    Badura, Susanne
    Tesanovic, Tamara
    Serve, Hubert
    Ruthardt, Martin
    Ottmann, Oliver G.
    BLOOD, 2010, 116 (21) : 1327 - 1327
  • [8] BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
    An, Xin
    Tiwari, Amit K.
    Sun, Yibo
    Ding, Pei-Rong
    Ashby, Charles R., Jr.
    Chen, Zhe-Sheng
    LEUKEMIA RESEARCH, 2010, 34 (10) : 1255 - 1268
  • [9] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
    Lee, Hyewon
    Basso, Igor Novitzky
    Kim, Dennis Dong Hwan
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (05) : 632 - 641
  • [10] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
    Hyewon Lee
    Igor Novitzky Basso
    Dennis Dong Hwan Kim
    International Journal of Hematology, 2021, 113 : 632 - 641
12345